Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (401-410 of 602) with videos related to

Pageof 61
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentMeletios A Dimopoulos, Pieter Sonneveld, Nelson Leung, et al.
British Journal of Haematology|June 13, 2022
Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myelomaJithma P Abeykoon, Julia Vaxman, Sanjay V Patel, et al.
American Journal of Hematology|January 2, 2023
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survivalCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Blood|August 16, 2017
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosisYi L Hwa, Rahma Warsame, Morie A Gertz, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
British Journal of Haematology|February 16, 2019
Substratification of patients with newly diagnosed standard-risk multiple myelomaMoritz Binder, S Vincent Rajkumar, Rhett P Ketterling, et al.
Blood Advances|April 12, 2022
Outcomes after biochemical or clinical progression in patients with multiple myelomaSarah Goldman-Mazur, Alissa Visram, Prashant Kapoor, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Leukemia & Lymphoma|July 15, 2021
Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysisAbdullah S Al Saleh, Alissa Visram, Harsh Parmar, et al.
Pageof 61

Showing results (401-410 of 602) with videos related to

Sort By:
Pageof 61
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentMeletios A Dimopoulos, Pieter Sonneveld, Nelson Leung, et al.
British Journal of Haematology|June 13, 2022
Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myelomaJithma P Abeykoon, Julia Vaxman, Sanjay V Patel, et al.
American Journal of Hematology|January 2, 2023
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survivalCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Blood|August 16, 2017
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosisYi L Hwa, Rahma Warsame, Morie A Gertz, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
British Journal of Haematology|February 16, 2019
Substratification of patients with newly diagnosed standard-risk multiple myelomaMoritz Binder, S Vincent Rajkumar, Rhett P Ketterling, et al.
Blood Advances|April 12, 2022
Outcomes after biochemical or clinical progression in patients with multiple myelomaSarah Goldman-Mazur, Alissa Visram, Prashant Kapoor, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Leukemia & Lymphoma|July 15, 2021
Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysisAbdullah S Al Saleh, Alissa Visram, Harsh Parmar, et al.
Pageof 61